"Our top three strategic priorities include forging synergic partnerships for our leading generic & research products, optimising organisational leverage to maximise our gains as well as astute capital investment", says Mr Saransh Chaudhary, CEO, Venus Medicine Research Centre (VMRC), and President, Critical Care Division, Venus Remedies in an exclusive interview with Geyatee Deshpande, Senior Research Associate, Dalal Street Investment Journal.